On March 17, 2021, Merck announced that it had filed a Form 10 registration statement with the U.S. Securities and Exchange Commission in order to spinoff its women’s health, biosimilars and established brands businesses into a standalone, publicly traded company, named Organon. Merck explained that Organon’s vision is to “create…